| Pharmaceutical Information |
| Drug Name |
Aclidinium |
| Drug ID |
BADD_D02465 |
| Description |
Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. |
| Indications and Usage |
Aclidinium bromide inhalation powder is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. |
| Marketing Status |
approved |
| ATC Code |
Not Available |
| DrugBank ID |
DB08897
|
| KEGG ID |
Not Available
|
| MeSH ID |
Not Available
|
| PubChem ID |
11434515
|
| TTD Drug ID |
D0VP1V
|
| NDC Product Code |
Not Available |
| UNII |
K17VY42F6C
|
| Synonyms |
Not Available |
|
| Chemical Information |
| Molecular Formula |
C26H30NO4S2+ |
| CAS Registry Number |
727649-81-2 |
| SMILES |
C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
